Vicept, Allergan deal

Allergan will acquire Vicept for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101, a topical cream targeting alpha adrenergic receptors on small blood vessels that has completed Phase II testing to treat erythema in patients with rosacea. Allergan would not provide a timeline for when it expects to begin Phase III testing. ...